Industries de la santé

IM Injections of PLX Cells Causing a Dramatic Recovery of Blood Forming Cells

HAIFA, ISRAEL, May 9, 2012 – Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE:PLTR) today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white...

Paris, le 3 mai 2012 - NYSE Euronext annonce aujourd'hui l'introduction de Vexim, un acteur de référence de la microchirurgie innovante du dos, sur NYSE Alternext à Paris.






Fondée en 2006 et basée à Toulouse, Vexim est spécialisée dans le traitement mini-invasif des fractures vertébrales par compression, et a entièrement conçu, développé et commercialisé SpineJack®...

HAIFA, ISRAEL, April 30, 2012 -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI; TASE: PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 11.8 million New Israeli Shekels (approximately $3.1 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Industry, Trade and Labor. Once received, the grant will be used...

LONDON, UK (GlobalData), 18 April 2012 - China and India are set to dominate the immunochemistry diagnostics market, according to a new report by medical intelligence company GlobalData.

The new report* found that the US presently takes monopoly in the immunochemistry market, largely due to above-average testing for drug abuse. However, emerging countries are anticipated to rise up and...

A Team of Internationally Renowned Physicians Will Collaborate on Advancing PLX Cell Therapies for Millions of People Suffering from the Chronic Disease



HAIFA, ISRAEL, April 3, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that it has formed a steering committee to assist in advancing PLacental eXpanded (PLX) cell therapies for the treatment of...

N°1 dans le Var, N°2 dans le Vaucluse et N°3 dans les Bouches-du-Rhône en nombre de laboratoires, JS BIO s’est hissé en 2 ans au rang de leader des acteurs de la biologie médicale en PACA. Cette structure fédérative de biologistes réunira 44 laboratoires fin mars et s’impose d’ores et déjà comme un acteur de la santé emblématique en matière de qualité et de niveau de...

Significantly improved cardiac function, smaller infarct size with greater regional left ventricle wall thickness and the pronounced stimulation of new vessels formation were observed in animals treated with PLX cells



HAIFA, ISRAEL, March 20, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that its PLacental eXpanded (PLX) cells, tested in a preclinical...

Scale up of bioreactors to allow production of about 30 billion cells with each reactor run

HAIFA, ISRAEL, March 12, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that it has initiated the process of scaling up the Company’s manufacturing bioreactors from their current size of 5 liter (L) to 15L. The up scaling process is being coordinated to go on-line...

Paris, le 7 Mars 2012 ‐ Sanofi annonce la mise à disposition dans les officines de Ipraalox® 20 mg, à base de pantoprazole, une nouvelle marque disponible en automédication.
Le reflux gastro‐oesophagien se manifeste par la remontée d'acide de l'estomac dans l’oesophage qui peut devenir inflammatoire et douloureux. Cette situation peut provoquer des symptômes tels une sensation de...

Vitrines Sociétés

Voir toutes les vitrines